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Cancer has touched or transformed the
lives of millions of people. The American
Cancer Society estimates that there are
about 1.2 million new cases of cancer per
year. Environmental factors, such as chem-
icals, radiation, and viruses, as well as
internal factors such as hormones and
inherited mutations, may all contribute to
development ofvarious cancers. Successful
diagnosis and treatment ofcancers relies in
part on detecting cancer cells within the
body. Recently, a team of researchers led
by Hans-Joachim Gross at the M.D.
Anderson Cancer Center developed a new
technique to detect very low levels of can-
cer cells in clinical samples ofnormal cells
in blood and bone marrow. This innova-
tive technique uses flow cytometry and
allows researchers to find 1 cancer cell in
10 million normal cells, a detection level
about 20 times more sensitive than is pos-
sible with current methods such as
immunocytochemistry and polymerase
chain reaction.
Applications
Current techniques for detecting low levels
of cancer cells can provide different types
of information for researchers and clini-
cians. For example, a blood sample from a
patient that is newly diagnosed with cancer
can be tested to determine if the cancer is
spreading to other areas. Patient blood
samples can also be tested after treatment
with chemotherapy to determine if the
number oftumor cells has decreased.
Another application of the detection
methods is for testing samples of bone
marrow that are removed from cancer
patients undergoing bone marrow trans-
plants. Bone marrow transplants are cur-
rently used to treat a variety ofblood can-
cers including leukemia, lymphomas, and
multiple myelomas, many ofwhich may be
environmentally mediated. Marrow trans-
plants may also be used as part ofa course
of therapy for nonhematologic diseases
such as solid tumors, immunological dys-
functions, and inherited enzyme defi-
ciencies. Gross's new flow cytometry assay
is primarily targeted for application as a
cancer treatment. In addition to being a
more sensitive cancer cell detection
method, the new flow cytometry assay is
unique in that it may someday be used to
remove cancer cells from a sample ofbone
marrow. Although some years away from
practical use, this process may eventually
decrease the likelihood of a cancer recur-
rence after the bone marrow transplant.
Flow Cytometry
Flow cytometry is based on analysis of
light scatter and staining from a continu-
ous sample ofcells as they pass a detector.
The light source is typically one or more
lasers. The detectors capture forward and
side scatter of light as each cell flows
through the analysis point. This highly
sensitive technique allows the characteris-
tics ofcells or other particles to be studied
in great detail.
Lasers are a good light source because
they can provide a bright, narrow, stable
beam. However, the color output of laser
light is very restricted. This disadvantage
restricts the choices of dyes that can be
visualized in a flow cytometer. Increasing
the number oflasers allows additional col-
ors to be visualized and increases the sensi-
tivity of the analysis. The flow cytometer
that Gross uses in the detection step con-
tains three lasers in a complex arrangement
that allows analysis of a large number of
experimental parameters, thereby increas-
ing the accuracy ofthe data.
In addition to measuring light scatter,
some flow cytometers can sort cells based
on the signal they emit. Cells can be
stained with antibodies linked to colored
dyes. Then, as the sample is run through
the sorter, all cells emitting a specific color
light signal (e.g., red) will be physically
shunted into a collection test tube, while
cells with other colors (e.g., green) will be
collected in a second tube. In his model
system, Gross used a FACS (fluorescence-
activated cell sorter) to sort BT-20 breast
carcinoma cells. The BT-20 cells were
labeled with a UV-excitable blue dye
called 7-amino-4-chloromethylcoumarin
(CMAC). This dye allowed the detector to
count the "blue" cells and deposit either 0,
40, 400, or 4,000 cells into four tubes
each containing approximately 1 x 108
peripheral blood stem cells. The purpose
was to create experimental samples with a
known number ofcancer cells. The mock
samples were run through a detector, and
the number ofcancer cells actually detect-
ed was matched against the number that
should have been detected.
A second flow cytometer with three
lasers was used for the detection step.
Researchers stained the BT-20 cancer cells
to distinguish them from the stem cells.
Several different antibodies against each
cell type were used to label the cell mixture
to ensure the most accurate detection. The
rare cancer cells were stained with three
antibodies linked to dyes that are yellow
and two shades ofred. The stem cells were
stained with a panel of five antibodies all
linked to a green dye called fluorescein
isothiocyanate. In his study, published in
the January issue of the Proceedings ofthe
National Academy ofSciences, Gross said,
"The requirement that the rare cancer cell
be simultaneously positive for three sepa-
rate colors and negative for a fourth color
[allows] detection of as few as one cancer
cell in 107."
The signal from the cell samples was
then transmitted to a computer which
generates a scatter plot ofthe BT-20 cells.
The blue CMAC dye originally used to
count the cancer cells was then used as a
final test to validate the results from the
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selective sorting of cancer and stem cells.
After the red and yellow cells were plotted,
these cells were examined under a UV
light. The presence of blue UV sensitive
dye in all ofthese cells helped confirm that
the assay was successful in sorting the can-
cer cells.
Better Marrow
Bone marrow is usually collected for an
autologous transplant when a patient is in
remission or early in the disease, but there
is a chance that cancer cells may also be
collected. In order to return marrow that is
as cancer-free as possible, some bone mar-
row transplant centers purge the marrow.
One common technique for purging uses a
cytotoxic agent to selectively damage can-
cer cells, but unfortunately it does not
completely spare the undiseased marrow
cells. Another technique, "negative selec-
tion," couples antibodies that recognize
and capture specific cancer cell marker
proteins to a solid matrix in a column or to
magnetic beads. The sample then is mixed
with the beads or run over the column and
the cancer cells are captured and removed.
A third, promising technique uses "positive
selection" to capture stem cells and to
remove cancer cells. This procedure uses
an antibody column that binds to a CD34+
marker on stem cells.
"In model studies," writes Gross, "bone
marrow with 10% tumor cell contamina-
tion can be purged by a factor of 10-3 to
i0o4. In a more realistic example with
0.1% tumor cell contamination, about
3,000 tumor cells could be returned into
the patient. To detect those cells in purged
bone marrow before infusion requires a
detection level ofone tumor cell per 106 to
107 cells, a level not achieved so far.
Present day methodologies . . permit a
level of detection by microscopy of one
tumor cell per 105 cells at best."
Gross asserts that one major applica-
tion for his technique is marrow sample
testing to improve diagnostic capability.
Unfortunately, a major roadblock for using
this process is the time needed to analyze
an entire marrow sample of 100 million
cells. As a sample ofcells drips through the
laser, about 6,000 "events" (light scatter
from a cell) per second are recorded by the
detectors. It may take up to seven hours to
analyze a typical sample, which is not a
clinically useful timeframe.
To address this concern, a company in
Palo Alto, California called SyStemix has
developed a high-speed flow cytometry sys-
tem designed to sort bone marrow cells.
SyStemix, which explores stem cell biology
and therapy, has developed a cytometer
that can analyze about 50,000 events per
second. In combination with a positive
selection column that reduces the total
number ofcells in the sample to be sorted,
this system reduces the sort time ofa typi-
cal sample to about one to two hours.
There is, however, a tradeoff between
reduced analysis time and the possibility of
increased stem cell damage that can result
from manipulation. Other laboratory tech-
nology companies are also working to
increase efficiency and decrease cost of
purging methods.
Even though removal of cancer cells
from reinfused marrow seems logical,
purging is a controversial topic among
researchers and clinicians. There is no solid
evidence to support whether a relapse is
caused by tumor cells in reinfused marrow
or by original tumor cells that survive the
ablation process. Many studies of autolo-
gous transplant patients have shown no
difference in survival between patients that
receive purged marrow versus those that
receive nonpurged marrow.
A prospective clinical trial conducted
by the European Bone Marrow Transplant
registry is attempting to provide data to
support or refute the benefits of marrow
purging. All trial centers are testing a stan-
dardized antibody-linked magnetic bead
technique. The results will not be available
for years because a large number of
patients must be recruited to complete the
c study.
UL: Meanwhile, cancer patients who receive
bone marrow transplants stand to benefit
from improved procedures that will aug-
ment their quality oflife and increase their
life expectancy. Improved detection tech-
niques will will also create new opportuni-
ties to research and study many types of
cancer in hope ofa cure.
Chris Edwards
Chris Edwards is a freelance journalist in Durham,
North Carolina.
Cell sleuth. Hans-Joachim Gross and colleagues atthe M.D. Anderson Cancer Center have developed a
cancer detection method that is one-in-ten-million.
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